Five-Year Data Support Neoadjuvant THP in ERBB2-Positive Breast Cancer
Neoadjuvant THP (paclitaxel + trastuzumab + pertuzumab) delivers excellent long‑term event‑free survival and recurrence‑free intervals with near‑universal ctDNA clearance in early‑stage ERBB2‑positive breast cancer.
In a prespecified secondary analysis of the phase‑2 DAPHNe trial, 98 patients with stage II‑III ERBB2‑positive breast cancer received 12 weeks of neoadjuvant THP. Five‑year follow‑up (median 5.2 yr) showed 99 % event‑free survival, 98 % recurrence‑free interval, and 99 % overall survival. Ultrasensitive ctDNA was detected in 89.5 % at baseline and cleared in 96.1 % after therapy, remaining <10 % post‑operatively. The data suggest superior long‑term efficacy of THP and potential prognostic value of ctDNA clearance.
HER2‑positive early‑stage breast cancer remains a high‑risk subgroup; demonstrating durable outcomes with neoadjuvant THP supports its use as a preferred frontline therapy and highlights ctDNA as a minimally invasive marker for therapeutic monitoring and relapse risk assessment.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC